Ceva Animal Health has launched new Gabbrovet Multi, which is now the first and only ready to use solution licensed to treat both cryptosporidium and Escherichia coli diarrhoea in calves.
Cryptosporidiosis is the most common cause of neonatal diarrhoea in calves under one month of age, while E. coli is considered the second most important pathogen affecting calves on UK farms (according to a FMR Global Health survey conducted in France, Germany, the UK, Belgium, Denmark, Poland and Spain in March 2022).
Neonatal diarrhoea not only contributes to increased mortality, reduced growth rate, delayed age at first calving and decreased milk production, but contact with infected livestock has been found to be the source of human cryptosporidium in up to 38 percent of cases.
Gabbrovet Multi contains paramomycin as its active ingredient and replaces Gabbrovet Solution.
In a study of 334 calves with severe diarrhoea, those receiving Gabbrovet Multi showed a faster and more effective response than those given halofuginone.
“Gabbrovet Multi is the first and only ready to use solution for the convenient treatment of both cryptosporidium and E. Coli, two of the most common causes of neonatal scour in calves,” comments Harry Walby, ruminant veterinary advisor at Ceva Animal Health.
“Alongside Gabbrovet Multi, Ceva also has a wide range of products to support the management of calves with scour including Meloxidyl, Rehydion and Diarsanyl.”
Gabbrovet Multi can be administered in milk or water. The ready to use solution is available with a dosing cap and it comes in 250 millilitres, 500 millilitres or 1 litre presentations.
For further information on Gabbrovet Multi, which also treats gastro-intestinal infections caused by E. coli in pigs, contact your local Ceva Animal Health territory manager or email cevauk@ceva.com.
